The Latin America, Middle East and Africa Inhalation and Nasal Spray Generic Drugs Market is expected to witness market growth of 11.9% CAGR during the forecast period (2022-2028).
When an inhaler is used incorrectly, very little or no medication gets to the lungs. Metered dosage inhalers, dry powder inhalers, and soft mist inhalers are the three main types of inhalers used to administer drugs for COPD and asthma. Over the following several years, more inhalers and nasal sprays are anticipated to enter the generic market. People are likely to incline toward more generic options if restrictive respiratory disorders, like asthma and chronic obstructive lung disease are diagnosed in more patients and as total health care costs stay high.
The generic market forecast for prescription pharmaceuticals for respiratory disorders is consistently positive, and the cheap cost of generic drugs allows significant space for expansion in this expanding business. An aggressive malignant brain tumor primarily encountered in adults is glioblastoma multiforme. Even with the most recent advancements in cancer therapies, the Blood-Brain-Barrier is still an obstacle for the few medications that have been able to penetrate it and directly target the tumor.
The gradual debilitating condition known as COPD is defined by enduring respiratory symptoms and airflow restriction brought on by anomalies in the airways brought on by prolonged exposure to noxious stimuli, air pollution, and inadequate pre- and postnatal lung development. The prevalence of this disorder is very high in Sub-Saharan Africa. Patients and doctors frequently fail to detect COPD, which results in underdiagnoses and undertreatment, especially in many SSA settings where the emphasis is still mostly on communicable diseases.
The Brazil market has highest market share in LAMEA Inhalation and Nasal Spray Generic Drugs Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $569.1 million by 2028. The Argentina market is estimated to witness a CAGR of 12.5% during (2022 - 2028).
Based on End-user, the market is segmented into Homecare, Hospitals, and Others. Based on Drugs Class, the market is segmented into Bronchodilators, Combination Drugs, Antihistamines, Corticosteroids, Decongestant Sprays, and Others. Based on Indication, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospitals Pharmacy, and Online Pharmacies. Based on Demographics, the market is segmented into Adult Patient, Geriatric Patient, and Pediatric Patient. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Akorn, Operating Company LLC, Cipla Limited, Teva Pharmaceuticals Industries Ltd., Novartis AG (Sandoz International GmBH), Apotex, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd., Beximco Pharmaceuticals Ltd.
When an inhaler is used incorrectly, very little or no medication gets to the lungs. Metered dosage inhalers, dry powder inhalers, and soft mist inhalers are the three main types of inhalers used to administer drugs for COPD and asthma. Over the following several years, more inhalers and nasal sprays are anticipated to enter the generic market. People are likely to incline toward more generic options if restrictive respiratory disorders, like asthma and chronic obstructive lung disease are diagnosed in more patients and as total health care costs stay high.
The generic market forecast for prescription pharmaceuticals for respiratory disorders is consistently positive, and the cheap cost of generic drugs allows significant space for expansion in this expanding business. An aggressive malignant brain tumor primarily encountered in adults is glioblastoma multiforme. Even with the most recent advancements in cancer therapies, the Blood-Brain-Barrier is still an obstacle for the few medications that have been able to penetrate it and directly target the tumor.
The gradual debilitating condition known as COPD is defined by enduring respiratory symptoms and airflow restriction brought on by anomalies in the airways brought on by prolonged exposure to noxious stimuli, air pollution, and inadequate pre- and postnatal lung development. The prevalence of this disorder is very high in Sub-Saharan Africa. Patients and doctors frequently fail to detect COPD, which results in underdiagnoses and undertreatment, especially in many SSA settings where the emphasis is still mostly on communicable diseases.
The Brazil market has highest market share in LAMEA Inhalation and Nasal Spray Generic Drugs Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $569.1 million by 2028. The Argentina market is estimated to witness a CAGR of 12.5% during (2022 - 2028).
Based on End-user, the market is segmented into Homecare, Hospitals, and Others. Based on Drugs Class, the market is segmented into Bronchodilators, Combination Drugs, Antihistamines, Corticosteroids, Decongestant Sprays, and Others. Based on Indication, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Rhinitis, and Others. Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospitals Pharmacy, and Online Pharmacies. Based on Demographics, the market is segmented into Adult Patient, Geriatric Patient, and Pediatric Patient. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Akorn, Operating Company LLC, Cipla Limited, Teva Pharmaceuticals Industries Ltd., Novartis AG (Sandoz International GmBH), Apotex, Inc., Hikma Pharmaceuticals PLC, Sun Pharmaceuticals Industries Ltd., Beximco Pharmaceuticals Ltd.
Scope of the Study
Market Segments Covered in the Report:
By End-user- Homecare
- Hospitals
- Others
- Bronchodilators
- Combination Drugs
- Antihistamines
- Corticosteroids
- Decongestant Sprays
- Others
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergic Rhinitis
- Others
- Retail Pharmacy
- Hospitals Pharmacy
- Online Pharmacies
- Adult Patient
- Geriatric Patient
- Pediatric Patient
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Viatris, Inc.
- Akorn, Operating Company LLC
- Cipla Limited
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG (Sandoz International GmBH)
- Apotex, Inc.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceuticals Industries Ltd.
- Beximco Pharmaceuticals Ltd.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Inhalation And Nasal Spray Generic Drugs Market by End-user
Chapter 4. LAMEA Inhalation And Nasal Spray Generic Drugs Market by Drugs Class
Chapter 5. LAMEA Inhalation And Nasal Spray Generic Drugs Market by Indication
Chapter 6. LAMEA Inhalation And Nasal Spray Generic Drugs Market by Distribution Channel
Chapter 7. LAMEA Inhalation And Nasal Spray Generic Drugs Market by Demographics
Chapter 8. LAMEA Inhalation And Nasal Spray Generic Drugs Market by Country
Chapter 9. Company Profiles
Companies Mentioned
- Viatris, Inc.
- Akorn, Operating Company LLC
- Cipla Limited
- Teva Pharmaceuticals Industries Ltd.
- Novartis AG (Sandoz International GmBH)
- Apotex, Inc.
- Hikma Pharmaceuticals PLC
- Sun Pharmaceuticals Industries Ltd.
- Beximco Pharmaceuticals Ltd.
Methodology
LOADING...
